BioShield II Patent Provision Under Fire From Drug Purchasers

Drug Industry Daily

A broad coalition of drug purchasers, insurance companies and trade associations is challenging a provision in a draft bioterrorism bill that would extend drug patents, arguing that the language would greatly increase costs by limiting the development of generic alternatives.

To View This Article:


Subscribe To Drug Industry Daily